Myomo Inc. · AMEX:MYO
Myomo — Investor Day (June 2025)
125 slides from Myomo's investor day presentation, Jun 18, 2025
Slide 1: Myomo Investor & Analyst Day
Myomo Investor & Analyst Day June 18, 2025 1
Slide 2: Agenda
Agenda • Direct Provider Business • Lead Generation • Field Operations • Reimbursement • Post-delivery Support • Manufacturing Tour and Overview • International Business • O&P Channel • Product Development • Finance • Wrap-Up and Q&A 2 Myomo, Inc. Analyst Day - June 18th 2025
Slide 3: Legal Disclaimer
Legal Disclaimer This presentation contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE American, the Company’s plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business, the Compan
Slide 4: Opening Remarks
Opening Remarks Paul R. Gudonis CEO 4
Slide 5: Paul R. Gudonis
Paul R. Gudonis Chairman & CEO • 40+ years experience in building new technology companies at scale • Cell Phone Service • Enterprise Software • Internet Services • Global Robotics Competition • Joined Myomo 15 years ago: 4-person spinout from MIT • Created new product category and market leadership
Slide 6: Purpose of Today's Investor / Analyst Day
Purpose of Today’s Investor / Analyst Day • Provide a “Deeper Dive” into Myomo’s operations • Meet members of Myomo’s Senior Leadership team • Tour our new HQ and Production facilities • Test your EMG Signal with a MyoPro demo unit • Provide details regarding our long-term business plan • We won't b
Slide 7: Myomo's Strategic Position
Myomo’s Strategic Position Created new product First-mover advantage Category with MyoPro in meeting a large and myoelectric orthosis growing unmet need CMS reimbursement Established direct Attractive margin profile opened access to provider business with with opportunity for Medicare-age population
Slide 8: Go-To-Market Model and Channels
Go-To-Market Model and Channels Direct Billing 79% of 1Q25 revenue VA 3% of 1Q25 revenue Myomo In-Country International 13% of 1Q25 revenue O&P Clinics US / O&P 5% of 1Q25 revenue Clinics 8 Myomo, Inc. Analyst Day - June 18th 2025
Slide 9: Next Milestone - Growing Revenue to Address a Large Unmet Need
Next Milestone - Growing Revenue to Address a Large Unmet Need 120 100 $100M 80 60 40 $32.4M 20 0 2024 2028 9 Myomo, Inc. Analyst Day - June 18th 2025
Slide 10: Myomo Leadership Team
Myomo Leadership Team Board of Directors CEO Paul Gudonis Commercial Engineering & Manufacturing Medical Affairs International Finance Operations Product Strategy Operations Dr. Harry Kovelman John Frijters Dave Henry Micah Mitchell Malcolm Bock Colin Anderson Marketing: Joseph Chicoskie Field Opera
Slide 11: Direct Billing Channel
Direct Billing Channel Micah Mitchell Chief Commercial Officer 11
Slide 12: Micah Mitchell
Micah Mitchell Chief Commercial Officer • Joined Myomo in 2018. • Oversees commercial operations with focus on expanding Myomo’s marketing, clinical sales and operations, clinical training, and distribution activities • 20+ years of experience providing high-end medical equipment to help disabled pe
Slide 13: Direct Provider Process - Overview
Direct Provider Process - Overview TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes 13 Myomo, Inc. Analyst Day - June 18th 2025
Slide 14: Direct Provider Process - Overview
Direct Provider Process - Overview TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Education via: • TV Ads • Social Media • Family/Friends • Physicians • Therapists • CPO’s 14 Myomo, Inc. Analyst Day - June 18th 2025
Slide 15: Successful Telehealth Screening = Pipeline Add
Direct Provider Process - Overview TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Patients’ first conversation(s) and/or telehealth screening and/or clinical evaluation to determine initial candidacy for a MyoPro. Successful Telehealth Screening = Pipeline
Slide 16: Successful Med Docs and/or Auth = Enter Backlog
Direct Provider Process - Overview TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Patient completes “face-to-face” with their Physician who orders the MyoPro and shares supporting medical records. Successful Med Docs and/or Auth = Enter Backlog 16 Myomo, In
Slide 17: Revenue Usually at Delivery
Direct Provider Process - Overview TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes • Capture shape of arm and hand • Find and/or train therapist • Custom fabricate each MyoPro • Deliver and final fitting • Patient to therapy: 10-12 weeks • MyoCare for ~first
Slide 18: Direct Provider Process - Overview
Direct Provider Process - Overview TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Education via: Patient completes • TV Ads “face-to-face” with • Capture shape of arm and hand • Social Media Patients’ first conversation(s) their Physician • Find and/or trai
Slide 19: Lead Generation
Lead Generation Joe Chicoskie Director of Marketing 19
Slide 20: Joseph Chicoskie
Joseph Chicoskie Director of Marketing • Joined Myomo in 2022 • Originally from Pittsburgh, PA, and lives in Dallas, TX • Marketing executive with corporate and advertising 20 agency experience • Refined marketing efforts to maximize lead generation while minimizing cost per pipeline addition 20 Myo
Slide 21: Lead Generation Efforts
Lead Generation Efforts TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Organic Efforts TV Ads educate the audience, Tradeshows generate leads, and lift results - Orthotists/Prosthetists from digital ads. Referrals - Therapists (OT & PT) - PM&R Physicians -
Slide 22: Facebook Creative Samples
Facebook Creative Samples 22 22 Myomo, Inc. Analyst Day - June 18th 2025
Slide 23: Facebook Creative Samples
Facebook Creative Samples 23 23 Myomo, Inc. Analyst Day - June 18th 2025
Slide 24: Advertising Spending
Advertising Spending TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Cost/lead in April was equal to a year ago 24 Myomo, Inc. Analyst Day - June 18th 2025
Slide 25: Advertising Cost Per Lead
Advertising Cost Per Lead TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes If there is a saturation point for digital and TV advertising directly to stroke patients, we are not experiencing it at this time. 25 Myomo, Inc. Analyst Day - June 18th 2025
Slide 26: Determinants of Cost Per Pipeline Add
Determinants of Cost Per Pipeline Add TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Customer Acquisition • Competition • Ad Strategy & Performance Cost/Lead • Seasonality • Other factors (politics, etc) Advertising • Operational Strategy & Cost per Lead Co
Slide 27: Conversion of Leads to Pipeline Adds
Conversion of Leads to Pipeline Adds A complex patient About half of each journey that may month’s pipeline adds come from take months, or leads generated years, to convert during that awareness into month, and the actions leading to rest come from an order. older leads. 27 Myomo, Inc. Analyst Day -
Slide 28: Time is a Factor in Pipeline Adds
Time is a Factor in Pipeline Adds TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes 35% Time from Initial Lead to Pipeline Add For those patients that enter the 30% Pipeline, many have an initial 25% interaction with us and then 20% pause the process. 15% 10%
Slide 29: Marketing Efficiency
Marketing Efficiency TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Marketing Efficiency Cost/Lead back to previous levels. Cost/Pipeline Add expected to be higher during rapid growth. Total $/Lead AD Spend/Pipeline Add 29 Myomo, Inc. Analyst Day - June 18t
Slide 30: Field Operations
Field Operations Micah Mitchell Chief Commerical Officer 30
Slide 31: Field Operations
Field Operations Fulfillment TH Med Docs Clinical Lead Gen Intake & Field Screening & Funding Outcomes Ops Field Operations Customer Regional MyoPro Experience Orthotists (RMO’s) Department (CXD) Patient Eligibility Team 31 Myomo, Inc. Analyst Day - June 18th 2025
Slide 32: Intake
Intake Fulfillment TH Med Docs Clinical Lead Gen Intake & Field Screening & Funding Outcomes Ops • 20 Intake Coordinators • Initial call with patient • Confirms paralyzed arm • Determines potential for funding • Schedules TH Screen with preference for “walk ins” • ~25,000 monthly inbound and outboun
Slide 33: Intake is Easily Scalable
Intake is Easily Scalable TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Intake Coordinators call volume for incoming and outgoing calls is increasing month over month with additional room for expansion and is easily scalable • 13 Intake Coordinators – June
Slide 34: Telehealth Screenings
Telehealth Screenings TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Patient View Clinician View • Team consists of 5 Patient Eligibility Specialists + manager, who are all clinicians • Telehealth Screenings confirm clinical candidacy and initiate the proce
Slide 35: Telehealth Screenings
Telehealth Screenings TH Med Docs Fulfillment Clinical Lead Gen Intake & Field Ops Screening & Funding Outcomes • Screening volume is increasing with additional capacity for growth • Approximately 40% of screened patients move forward and are considered a pipeline add 35 Myomo, Inc. Analyst Day - Ju
Slide 36: Screening Holds
Screening Holds TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes • Patients must pass strict clinical inclusion/ exclusion criteria for pipeline add. Approx. 60% are placed on hold • Some considerations are: Tone/ spasticity, range of motion, strength, EMG si
Slide 37: Example of a typical screening
TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes • Example of a typical screening by a Patient Eligibility Specialist 37 Myomo, Inc. Analyst Day - June 18th 2025
Slide 38: Team of Highly Qualified CPO's
Team of Highly Qualified CPO’s TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Luis Capestany Jack Coleman Janae Halter Matt Beale Mel Carver Olivia Sheffer – Field Operations Manager 38 Sam Mitchell Sarah Bui Sean Allen Kyle Sherk Logan Goedde Cody Dean – F
Slide 39: Fulfillment
Fulfillment TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes When a patient begins the fulfillment process, they exit the Pipeline and enter the Backlog FULFILLMENT: Shape Capture– In person or remote by licensed CPO – (Regional MyoPro Orthotist) Fabrication–
Slide 40: We Will Come To You – Wherever You Are
We Will Come To You – Wherever You Are TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes 14 Regional MyoPro Orthotists territories 40 Myomo, Inc. Analyst Day - June 18th 2025
Slide 41: Medical Affairs
Medical Affairs Harry Kovelman, MD Chief Medical Officer 41
Slide 42: Harry Kovelman, MD
Harry Kovelman, MD Chief Medical Officer •Live in Baltimore, MD •Over 25 years in leadership roles in medical device and pharmaceutical industry and lead communicating the Company’s scientific message to the payer community, clinicians, and patients. •Roles as Global Medical Director for Orthopedics
Slide 43: Collection of medical records and a physician's order
TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Collection of medical records and a physician’s order proceed the Fulfillment process. 43 Myomo, Inc. Analyst Day - June 18th 2025
Slide 44: Patient and Market Access Update
Patient and Market Access Update TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Blues and Successful Commercial Part B Appeals! MAOs United Healthcare Medicare Part B 44 Myomo, Inc. Analyst Day - June 18th 2025
Slide 45: Medical Affairs Department
Medical Affairs Department TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Patient Navigators - (15) with one Director and two leads • Guide patients through the Myomo journey • Obtain medical necessity documentation from providers Clinical Appeals Specialis
Slide 46: Revenue by Major Payer
Revenue by Major Payer TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Q1 2023 Q1 2025 23% 18% Payer Mix has changed dramatically 47% Medicare coverage 53% Med Advantage utilization management 59% Med Advantage Other Med Advantage Medicare Other 46 Myomo
Slide 47: State of MAO Authorization Rates
State of MAO Authorization Rates TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Industry-wide MAO denial rates are in increasing, and MAO profitability is on the decline MAO Auth Rate 40% 35% 30% This has incentivized MAO plans to more tightly control utili
Slide 48: Overcoming Payer Denials
Overcoming Payer Denials TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes TOP THREE MOST COMMON REASONS Experimental / Not Medically Not Covered by Original Investigational Necessary Medicare AHA Guidelines Medicare Program Integrity Medicare Fee Schedu
Slide 49: Medicare Advantage Timeline to ALJ and Decision
Medicare Advantage Timeline to ALJ and Decision ….. a 5-10 month process! TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes 2nd Denial / Case PA 1st Appeal 1st Denial Forwarded to Submission Submitted Maximus 14-30 days 14-30 days 30-60 days Maximus Request AL
Slide 50: Administrative Law Judge (ALJ) Hearings
Administrative Law Judge (ALJ) Hearings TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes • When a denial is upheld by the Independent Review Entity (IRE), Maximus, a case is eligible for ALJ Hearing ALJ Hearing Results YTD • An ALJ Hearing is a telephonic hea
Slide 51: MAO's obligations under Medicare
MAO’s have statutory, regulatory and contractual obligation under Medicare TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes MAOs must cover everything that is reasonable and medically necessary for Medicare beneficiaries and must cover all services and device
Slide 52: Myomo Approach / Road to Broader Reimbursement
Myomo Approach / Road to Broader Reimbursement TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes PLAN • Continue Appeals • Increase Number of ALJ Hearings • Even with legal fees, still provides a good contribution margin activity • Publish MEO Review Paper and
Slide 53: In-Network Provider Contracts
In-Network Provider Contracts- Case by Case Basis, Established Pricing, Faster Cycle Times and Approximately 27.2 Million Lives Covered; Can Lead to Policy Change TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Payer Effective Date Payer Effective Date BCBS
Slide 54: Clinical Outcomes
Clinical Outcomes Kathy Sawyers, PT, ATP Sr. Director – Clinical Outcomes 54
Slide 55: Kathy Sawyers, PT, ATP
Kathy Sawyers, PT, ATP Sr. Director - Clinical Outcomes • Physical Therapist with 30+ years of experience in patient care, clinical operations, and healthcare leadership • Primary focus is on enhancing clinical outcomes for Myomo clients • Manages internal and external clinical training and oversees
Slide 56: Framing the Problem: Upper Extremity Paresis
TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Framing the Problem: Upper Extremity Paresis 800,000 patients are affected by stroke in the USA per year Results in 250,000 patients with Chronic Arm Weakness 56 Myomo, Inc. Analyst Day - June 18th 2025
Slide 57: Myoelectric Technology
Myoelectric Technology TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes The MyoPro combines existing myoelectric Myoelectric Robotics technology with Prosthetics neurorehabilitation principles and training Neuro Rehab techniques MyoPro 57 Myomo, Inc. Analyst
Slide 58: Lead Gen Intake TH
TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes 58 Myomo, Inc. Analyst Day - June 18th 2025
Slide 59: MARK2 Mobile Arm Rehabilitation Kit
MARK2 Mobile Arm Rehabilitation Kit TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes 59 Myomo, Inc. Analyst Day - June 18th 2025
Slide 60: MyoPro 2x Motion G / MyoPro 2+ Motion W
TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes MyoPro 2x Motion G MyoPro 2+ Motion W 60 Myomo, Inc. Analyst Day - June 18th 2025
Slide 61: Donning Objectives of the MyoPro 2x
TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Donning Objectives of the MyoPro 2x: Simplify the donning experience Promote greater independence for the user with donning Dorsal Hand Strap Thenar Hand Strap 61 Myomo, Inc. Analyst Day - June 18th 2025
Slide 62: Lead Gen Intake TH
TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes 62 Myomo, Inc. Analyst Day - June 18th 2025
Slide 63: Boots on the Ground All over the U.S.
Boots on the Ground All over the U.S. TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Therapy and Patient Trainers Support both Direct Billing and O&P Channels 63 Myomo, Inc. Analyst Day - June 18th 2025
Slide 64: Over 1600 MyoPro Trained Therapists
TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Over 1600 MyoPro Trained Therapists 64 Myomo, Inc. Analyst Day - June 18th 2025
Slide 65: The P.E.R.L. Program
TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Eat Reach Lift Push The P.E.R.L. Program - structured guidelines on how to incorporate the MyoPro into therapy Recommend a minimum of 10 -12 weeks of therapy Suggest 1:1 therapy sessions for 45 – 60 minut
Slide 66: Certification Training
Certification Training TH Med Docs Fulfillment Clinical Lead Gen Intake Screening & Funding & Field Ops Outcomes Patient Selection and Evaluation Training MyoPro 2x Device Overview MyoPro 2x Fitting Guidelines Certification Test 66 Myomo, Inc. Analyst Day - June 18th 2025
Slide 67: Meet Sandra
TH Med Docs Fulfillment Clinical Lead Gen Intaken Screening & Funding & Field Ops Outcomes Meet Sandra 62 years old Stroke at age 37 Right arm weakness Minimal tone/spasticity 67 Myomo, Inc. Analyst Day - June 18th 2025
Slide 68: Manufacturing Tour
myomo my own motion Manufacturing Tour
Slide 69: BREAK
myomo my own motion BREAK
Slide 70: Manufacturing
Manufacturing Colin Anderson Director of Global Operations 70
Slide 71: Colin Anderson
Colin Anderson Director of Global Operations • Global Director of Operations at Myomo since 2023, overseeing manufacturing, supply chain, fulfillment, and engineering. • 15+ years of medical device industry experience, leading cross- functional teams in scaling operations, new product launches, and
Slide 72: Making a MyoPro
Making a MyoPro 72 72 Myomo, Inc. Analyst Day - June 18th 2025
Slide 73: Manufacturing Process Map
Manufacturing Process Map 3D Printing Supplier Technical Service & Customer Repair Support Model First Station/ In-Process Shape Capture Final Assembly Kitting Final Inspection Shipping Generation Subassemblies Inspection User User Laptops Motor Kit Manuals Assemblies Batteries/ Chargers 73 Myomo, I
Slide 74: Shape Capture and Model Generation
Shape Capture Final 1st Station & In-Process Final & Model Kitting Inspection & Subassemblies Inspection Assembly Generation Ship • Shape Capture Kits are ready to ship to customers for in person or remote shape capture. • Model Generation customizes the dimensions of each device to the user’s anato
Slide 75: First Station and Subassemblies
Shape Capture Final 1st Station & In-Process & Model Final Assembly Kitting Inspection & Subassemblies Inspection Generation Ship • Build custom subassemblies • Supplier produces the custom for each device based on orthotic shells user’s measurements 75 Myomo, Inc. Analyst Day - June 18th 2025
Slide 76: In-Process Inspection
Shape Capture Final 1st Station & In-Process & Model Final Assembly Kitting Inspection & Subassemblies Inspection Generation Ship • Dimensionally verify all components at in-process inspection prior to assembly 76 Myomo, Inc. Analyst Day - June 18th 2025
Slide 77: Final Assembly
Shape Capture Final 1st Station & In-Process & Model Final Assembly Kitting Inspection & Subassemblies Inspection Generation Ship • Subcomponents are fastened together with rivets, screws, glue, pins, etc. • Several workstations set up for final assembly • Cables are routed neatly through the device
Slide 78: Kitting
Shape Capture Final 1st Station & In-Process & Model Final Assembly Kitting Inspection & Subassemblies Inspection Generation Ship •Devices are kitted with: •Spare batteries •Charger •Manuals •Laptop •Carrier Bag 78 Myomo, Inc. Analyst Day - June 18th 2025
Slide 79: Final Inspection and Ship
Shape Capture Final 1st Station & In-Process & Model Final Assembly Kitting Inspection & Subassemblies Inspection Generation Ship • Several Final Inspection Stations • A kitted device arrives at the station and a full functional test is conducted to ensure the device • Devices are packaged after is
Slide 80: Manufacturing Update – The Past Year
Manufacturing Update – The Past Year • Scaled capacity proportionately with demand • Moved to Burlington January 2025 80 • Capacity can be further increased with a 2nd shift 80
Slide 81: Phase I – Burlington
Phase I – Burlington • We outgrew our Boston HQ and moved to Burlington, MA. • New Facility was designed for better 81 process flow and efficiency 81
Slide 82: Phase II Expansion: Key Objectives
Phase II Expansion: Key Objectives Improvements Business Objectives Office • Add 18 cubicles Increased Capacity: Facilitate growth to 250 units/month Expansion for • Add 3 offices New Hires • Add 1 conference room Streamline Product and Process Flow Production • New flexible production space Capacit
Slide 83: Phase II: On Track for July
Phase II: On Track for July • Doubled First Floor Footprint • Enable insourcing of core subassemblies • Expanded Service area • Flex Production Space for New Products (MyoPro 3) • Expanded Engineering Model Shop and Reliability Lab • Increased Stockroom Capacity 83
Slide 84: Cost Reduction and Risk Mitigation
Cost Reduction and Risk Mitigation • Provide a Second Internal Source for: • FE & SP Joint – Q4 2025 Target – 15% Cost Reduction (estimate) • Grasp and Elbow Motor Assembly – Q1 2026 Target – 15% Cost Reduction (estimate) • Laptop Elimination: • Part of Companion App Project Launch • Majority of dev
Slide 85: International Operations
International Operations John Frijters Managing Director Myomo Europe GmbH 85
Slide 86: John Frijters
John Frijters Managing Director - Myomo Europe GmbH • Joined Myomo in 2020 • Currently residing in Göttingen, Germany • Previous executive roles in product management, sales and marketing and business development at ReWalk and Ottobock • Executive MBA from Kellog-WHU Global Program 86 Myomo, Inc. An
Slide 87: International Revenue – Germany & ROW
International Revenue – Germany & ROW $5.000.000 Revenue in USD Germany; Revenue - 2024 $4.500.000 96% $4.000.000 2022 2023 2024 $3.500.000 $3.000.000 $2.500.000 $2.000.000 International - $1.500.000 Other; 4% 2022 2023 2024 Germany International - Other Revenue $1.931.544 $3.284.176 $4.512.208 Busi
Slide 88: Reimbursement Environment in Germany
Reimbursement Environment in Germany • Approximately 82 million individuals in Germany possess health insurance. • Around 150,000 stroke survivors are recorded annually. • MyoPro has secured funding from over 50 insurance providers. • Funding eligibility for MyoPro has been validated by the Social C
Slide 89: MyoPro Patient Journey in Germany
MyoPro Patient Journey in Germany Step 1 - Patient Identification & Connect Step 4 - Reimbursement & Approval Step 2 - Clinical Evaluation & Screening Step 5 - Device Fabrication & Delivery Step 3 - Documentation & Justification Step 6 - Training, Use & Follow-Up Funding approval for a MyoPro freque
Slide 90: From Funding to Revenue - Germany
From Funding to Revenue - Germany 10% Funding to Direct Fitting • 10% Submission of request for funding results in direct approval for a MyoPro fitting • User receives MyoPro Device and ADL Training supported by Myomo in average after 220 days 65% of Funding Request are routed through a 6 month Tria
Slide 91: MyoPro Revenue Distribution - Germany
MyoPro Revenue Distribution - Germany Direct Fitting 10% Funding to Revenue Direct Fitting; Conversions; 10% Trials 35% − Trial duration approx 6 months − 35% conversion rate − Additional conversions after appeal/ SG appeal − Backed Up by Myomo Clinical Trainers MyoCare Trials; 65% 35% Conve
Slide 92: Organizational Development
Organizational Development Plan 2025 Enhance the team from 12 (12.2024) to 20 by end of 2025 − Cover open areas 0 5 10 15 20 25 − Handle growing number of inquiries and trials GmbH 2 2 − Grow trial conversation rate, defend market position Team Myomo GmbH − Build pipeline for 2026 CTM 6 11 Scali
Slide 93: Development & Growth Initiatives
Development & Growth Initiatives Grow Referring Increase Coverage & Smart and Digital Scaling the GmbH Operation Medical Specialist Awareness Processes Network Larger team Social Media Online Pre-Screening Visits to OT/PT therapist, Smaller areas doctor, clinic, CPO Print Integrate MS Dynamics 365 H
Slide 94: Long Term Revenue
Long Term Revenue Business Growth $15.000.000 $13.000.000 $11.000.000 35% CAGR $9.000.000 $7.000.000 52% CAGR $5.000.000 94 $3.000.000 $1.000.000 2022 2023 2024 2028 Revenue is projected to grow to $15 million by 2028, reflecting strong market momentum and strategic execution. 94 Myomo, Inc. Analyst
Slide 95: O&P Channel
O&P Channel Micah Mitchell Chief Commercial Officer 95
Slide 96: O&P Channel Primer
O&P Channel Primer SCOPE • Licensed clinicians assess, design, fabricate, fit, and monitor • Serves patients with musculoskeletal, neurological, and amputation-related conditions • Insurance in-network contracts generally in place MARKET TRENDS • Focus on patient outcomes and clinical data • Some co
Slide 97: Customer quote: Aaron Sorensen
“We are looking to expand some of our technology offerings, both in prosthetics and orthotics. And obviously, the MyoPro fits right into that initiative.” Aaron Sorensen Owner /LCPO Restorative Health Services Group in Murfreesboro, TN 97 Myomo, Inc. Analyst Day - June 18th 2025
Slide 98: O&P Channel Updates
O&P Channel Updates O&P Channel launch, post MyoPro2x with full MyoPro certification to allow COE’s to order without our involvement, is going well, with signs of growth. Can we get commitment from O&P leaders and clinicians? Can we successfully train CPO’s on clinical aspects? Can we train COE’s to
Slide 99: O&P Channel – Eval Training and Certification Process
O&P Channel – Eval Training and Certification Process • Learn about • On Demand • 8-12 Hours MyoPro • Then COE • 3+ MARK evals • Agree to builds pipeline Eval Day • In-Services COE Pricing, Terms Initial Eval – at least 3 Certification • COE builds Commits & Conditions Training patients Step 1 Pipel
Slide 100: Customer quote: Jason Auyer
“I’ve been excited about this since 2013 when I was first exposed to the MyoPro. And now with Medicare having a code for this, this is going to be able to provide really life changing orthotic care for patients that we really have not been able to do in the past.” Jason Auyer Owner / LCPO Alliance P
Slide 101: O&P Channel Updates
O&P Channel Updates Infrastructure and leaders now in place Rapid growth expected for next few years 101 Myomo, Inc. Analyst Day - June 18th 2025
Slide 102: O&P Channel Updates: 2028 Projection Range
O&P Channel Updates 2028 Projection Range 102 Myomo, Inc. Analyst Day - June 18th 2025
Slide 103: Customer quote: Roger Mermelstein
“Our goal is to get 20 referrals over the next three to four months that ” turn into five to seven [MyoPro] patients. Roger Mermelstein US Operations EqwalGroup in Washington D.C. 103 Myomo, Inc. Analyst Day - June 18th 2025
Slide 104: Product Development
Product Development Malcolm Bock V.P. Engineering and Product Strategy 104
Slide 105: Malcolm Bock
Malcolm Bock VP Engineering & Product Strategy • Joined Myomo in 2023 • 30+ years experience in electro-mechanical medical device product development across both small/start-up, medium, and large companies, including Respiratory Motion, Bionik Labs and Covidien/Medtronic • Spans products including D
Slide 106: Product Roadmap
Product Roadmap 106 Myomo, Inc. Analyst Day - June 18th 2025
Slide 107: MARK 2 (Launched January 2025)
MARK 2 (Launched January 2025) Mobile Arm Rehabilitation Kit : Used by Clinicians to evaluate suitability of MyoPro for each unique candidate/user: New version of the device incorporated the following improvements: • 3D printed shells • ‘One Size Fits All’ design featuring built in adjustability (Fo
Slide 108: MyoPro 2x (Launched April 2025)
MyoPro 2x (Launched April 2025) MyoPro 2x is a redesign of the mechanical orthotic elements to minimize donning time and improve sensor contact. The following key improvements were integrated into MyoPro 2x: • Improved Hand Strap, Shell, & Motor Closure • Improved Forearm and Humeral Shell design fo
Slide 109: MyoPro 2x Training Video (80 sec.)
MyoPro 2x Training Video (80 sec.) 109 Myomo, Inc. Analyst Day - June 18th 2025
Slide 110: MyoPro Companion App
MyoPro Companion App (2x & Mark 2) to Serve as the Key Communication Platform for the Future • Reduced COGS - leveraging patient’s existing mobile device as opposed to supplying a new laptop with each device delivery • Improved reliability due to decreased reliance on third-party materials such as l
Slide 111: Competition (Germany)
Competition (Germany): Slimmer, but more limited addressable market Competitor Advantage: Smaller more modern look Vincent Systems Neo1 • Smaller motor and slightly smaller battery reduce the device footprint • Adjustable buckles add a modern look and easy to use • Simplified hand donning—finger pie
Slide 112: MyoPro3: Maximizing Patient Functional Outcomes
MyoPro3: Maximizing Patient Functional Outcomes • Goal is to restore “the functions of the patient’s weak limbs.” • Further enhanced functionality will be measured against: –Validated outcome measures (objective measurements of functionality) –Patient reported outcomes (subjective patient reports) M
Slide 113: MyoPro3 Expected to Leverage the Latest Technological Advancements
MyoPro3 Expected to Leverage the Latest Technological Advancements to Enhance Patient Function • Donnability: Intuitive design with more comfortable cuff materials and improved closure system • Reliability: Increased patient utilization and satisfaction with reliable, consistent, predictable, and sm
Slide 114: MyoPro 3 Key Technologies
MyoPro 3 Key Technologies Electronics Pack Shoulder Harness Robotic Elbow Orthosis/Bracing Orthosis/Structure Robotic Grasp EMG Sensing 114 Myomo, Inc. Analyst Day - June 18th 2025
Slide 115: MyoPro 3 Expected to Provide
MyoPro 3 Expected to Provide Modular platform technology to support future new product releases and enhancements Design to the subjective and objective tests for strongest payer reimbursement positioning and enabling meaningful user function. Proactive monitoring and state-of-the- art core technolog
Slide 116: Finance
JI fel Finance David Henry CFO
Slide 117: David Henry
David Henry Chief Financial Officer • CFO at Myomo since 2019. • Prior to Myomo, I was CFO at EOS Energy Storage (pre-SPAC), American Superconductor Corp and AMI Semiconductor Corp. Nearly 20 years as public-Company CFO • Broad background in Finance and Accounting, including Controller, Financial An
Slide 118: Financial Snapshot
Financial Snapshot Revenue Gross Margin $14.0 80.0% $12.0 75.0% $10.0 70.0% $8.0 65.0% $6.0 60.0% $4.0 $2.0 55.0% $- 50.0% Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Operating Expenses Pipeline Adds and Backlog $12.0 800 350 700 $10.0 300 600 $8.0 500 250 400 $6.0 300 20
Slide 119: Components of Spending
Components of Spending Q1 2025 Operating Expenses Q1 2025 COGS 120% 9% Payroll & Benefits 2% 2% Advertising 100% 3% 5% Consultants 80% Other Overhead Travel Warranty 6% 52% Outside Services 60% Rent 7% Legal Payroll + Benefits Rent (opex portion) 40% Material Depreciation 16% 20% All Other 0% 68% of
Slide 120: Cash Position
Cash Position Operating Cash Flow $4.0 $3.0 $2.0 $1.0 $- $(1.0) • $4M line of credit - $1.9M available $(2.0) • $3M term loan facility $(3.0) • Both facilities undrawn $(4.0) Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 As previously disclosed, negative Operating Cash Flow in Q2 is expected to be greater tha
Slide 121: Long Term Model - $100M in Revenue by 2028
Long Term Model - $100M in Revenue by 2028 Revenue 120 100 Other LT targets: 80 • Gross Margin: 70 – 72% Revenue $M CAGR = 32% 60 • EBITDA Margin: 15% - 20% • Cash Flow Breakeven 40 Revenue: $17M-$18M per quarter 20 0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2028 121 Myomo, Inc. Analyst Day - Ju
Slide 122: Model Revenue by Channel
Model Revenue by Channel Model Revenue by Channel at $100M Q1'25 Revenue by Channel 15% 13% 3% 3% 5% 20% 79% 62% Direct Billing US O&P VA International Direct Billing US O&P VA International 122 Myomo, Inc. Analyst Day - June 18th 2025
Slide 123: How Do We Achieve the LT Targets?
How Do We Achieve the LT Targets? • Continue direct billing efforts. Approximately 25% annual revenue growth, assuming modest improvement in some conversion rates. • U.S. O&P channel is a large growth driver. Based on earlier sensitivity analysis –we believe our model O&P revenue is in the “middle o
Slide 124: Takeaways
Takeaways • Our target is to achieve $100 million in annual revenue by 2028. • O&P channel targeted to be 20% revenue by 2028. • Revenue level for operating cash flow breakeven is ~$17M - $18M per quarter. • We’ll spend the advertising dollars necessary to ensure continued growth in the direct billi
Slide 125: Closing Remarks
Closing Remarks Paul Gudonis CEO 125